Psoriasis

August 01, 2022

The cream's approval, based on findings from the phase 3 DERMIS trial, makes the topical PDE4 inhibitor the first of its kind approved for treating plaque psoriasis.

May 12, 2022

Data from the POETYK PSO long-term extension (LTE) trial showed deucravacitinib was clinically effective and safe for treating adult patients with moderate-to-severe plaque psoriasis.

April 26, 2022

Jeffrey Stark, MD, discusses the latest bimekizumab and certolizumab pegol data presented at the 2022 American Academy of Dermatology annual meeting.

January 20, 2022

Deucravacitinib selectively binds to a unique pocket in the regulatory domain of TYK2 instead of the highly conserved active site of the catalytic domain,” investigators explained. “This leads to targeted inhibition of immune pathways that are central to psoriasis while limiting off-target effects.”

October 18, 2021

Jeffrey Stark, MD, discusses the recent studies, BE BRIGHT, BE SURE, and BE VIVID, in which investigators analyzed the impact bimekizumab had on patients with psoriasis.

March 18, 2021

Guselkumab is the first and only approved IL-23 inhibitor therapy used to treat adults with active PsA and moderate to severe plaque psoriasis (PsO). The medication showed efficacy in skin clearance and joint symptom relief and passed safety measures. Additionally, physical function, health-related quality of life, and resolution of enthesitis and dactylitis were confirmed through week 100.

October 02, 2020

Researchers writing in JAMA Dermatology report that latent tuberculosis infection previously assumed to be an adverse event as a result of treatment with secukinumab, is actually uncommon in patients with chronic systemic inflammatory conditions.

November 27, 2019

Children with inflammatory bowel disease, juvenile idiopathic arthritis, and chronic noninfectious osteomyelitis who were treated with TNF inhibitors had a higher rate of incident psoriasis than those not exposed to these biologics, say researchers recently writing in Arthritis Care & Research.

July 15, 2019

Patients with severe psoriasis are also at a significant increase for developing advanced liver fibrosis, new research shows

May 30, 2019

Psoriasis patients have a lower risk of serious infection with specific biologic and non-biologic medications than with methotrexate, based on new research results.